Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P40189: Variant p.Ala517Pro

Interleukin-6 receptor subunit beta
Gene: IL6ST
Feedback?
Variant information Variant position: help 517 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Alanine (A) to Proline (P) at position 517 (A517P, p.Ala517Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and hydrophobic (A) to medium size and hydrophobic (P) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In HIES4B; results in impaired cytokine-mediated signaling pathway with loss of response to IL-6, IL-11, IL-27 and reduced response to OSM, CNTF and LIF. Any additional useful information about the variant.


Sequence information Variant position: help 517 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 918 The length of the canonical sequence.
Location on the sequence: help TPVYADGPGSPESIKAYLKQ A PPSKGPTVRTKKVGKNEAVL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         TPVYADGPGSPESIKAYLKQAPPSKGPTVRTKKVGKNEAVL

Mouse                         TPVFATGPGGSESLKAYLKQAAPARGPTVRTKKVGKNEAVL

Rat                           TPVFPGGPGSPESMKAYLKQAAPSKGPTVRTKKVGKNEAVL

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 23 – 918 Interleukin-6 receptor subunit beta
Topological domain 23 – 619 Extracellular
Domain 426 – 517 Fibronectin type-III 4
Alternative sequence 330 – 918 Missing. In isoform 2.



Literature citations
Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome.
Chen Y.H.; Zastrow D.B.; Metcalfe R.D.; Gartner L.; Krause F.; Morton C.J.; Marwaha S.; Fresard L.; Huang Y.; Zhao C.; McCormack C.; Bick D.; Worthey E.A.; Eng C.M.; Gold J.; Montgomery S.B.; Fisher P.G.; Ashley E.A.; Wheeler M.T.; Parker M.W.; Shanmugasundaram V.; Putoczki T.L.; Schmidt-Arras D.; Laurence A.; Bernstein J.A.; Griffin M.D.W.; Uhlig H.H.;
J. Allergy Clin. Immunol. 148:585-598(2021)
Cited for: VARIANT HIES4B PRO-517; CHARACTERIZATION OF VARIANT HIES4B PRO-517;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.